Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia

Palliative care in acute myeloid leukaemia (AML) is inadequate. For elderly patients, unfit for intensive chemotherapy, median survival is 2–3 months. As such, there is urgent demand for low-toxic palliative alternatives. We have repositioned two commonly administered anti-leukaemia drugs, valproic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Leitch, Calum, Osdal, Tereza, Andresen, Vibeke, Molland, Maren, Kristiansen, Silje, Nguyen, Xuan Nhi, Bruserud, Øystein, Gjertsen, Bjørn Tore, McCormack, Emmet
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4884979/
https://ncbi.nlm.nih.gov/pubmed/26812881
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6991
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados